The LUX-Lung 5 results have yet not let to changes in second-line treatment recommendations in terms of combining EGFR inhibition with cytotoxic chemotherapy post-progression in patients with EGFR-mutant NSCLC who initially responded to EGFR TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.